Robert Lisicki
Chief Executive Officer chez ZURA BIO LIMITED
Fortune : - $ au 31/03/2024
Profil
Mr. Robert Lisicki is a Chief Executive Officer & Director at Zura Bio Ltd.
He is on the Board of Directors at Zura Bio Ltd., Adiso Therapeutics, Inc. and Cadrenal Therapeutics, Inc. Mr. Lisicki was previously employed as a Chief Executive Officer & Director by InCarda Therapeutics, Inc., a Chief Commercial Officer & Executive VP by Arena Pharmaceuticals, Inc., a Chief Customer Officer, SVP-Sales & Marketing by Daiichi Sankyo, Inc., a Vice President & General Manager by Amgen, Inc., and a General Manager & Vice President-Cardio Metabolic by Regeneron Pharmaceuticals, Inc. He received his undergraduate degree from State University of New York at Albany.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 07/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Robert Lisicki
| Sociétés | Poste | Début |
|---|---|---|
| CADRENAL THERAPEUTICS, INC. | Director/Board Member | 23/07/2023 |
| ZURA BIO LIMITED | Chief Executive Officer | 08/04/2024 |
Adiso Therapeutics, Inc.
 Adiso Therapeutics, Inc. BiotechnologyHealth Technology Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022. | Director/Board Member | 12/10/2023 |
Anciens postes connus de Robert Lisicki
| Sociétés | Poste | Fin |
|---|---|---|
InCarda Therapeutics, Inc.
 InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Chief Executive Officer | 01/03/2023 |
| ARENA PHARMACEUTICALS | Corporate Officer/Principal | 01/03/2022 |
Daiichi Sankyo, Inc.
 Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Sales & Marketing | 01/04/2018 |
| AMGEN INC. | Corporate Officer/Principal | - |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Robert Lisicki
| State University of New York at Albany | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| ZURA BIO LIMITED | Health Technology |
| Entreprise privées | 5 |
|---|---|
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Health Technology |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Health Technology |
Adiso Therapeutics, Inc.
Adiso Therapeutics, Inc. BiotechnologyHealth Technology Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022. | Health Technology |
| Cadrenal Therapeutics, Inc. |
